Ambrosia, a biotech startup, secured $100 million in Series B funding led by ARCH Venture Partners and RA Capital Management.
The funding will accelerate development of oral small molecule GLP-1 receptor agonists as next-gen alternatives to injectable drugs like Ozempic.
Small molecule GLP-1s aim for better patient compliance, lower costs, and improved efficacy in treating obesity and type 2 diabetes.
The round brings Ambrosia's total funding to over $150M; preclinical data shows promising potency and oral bioavailability.
Announcement made March 25, 2026; company plans Phase 1 trials in 2027.